Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 24
- Registration Number
- NCT00392782
- Locations
- 🇺🇸
Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 146
- Registration Number
- NCT00382109
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
- Conditions
- Interventions
- Biological: anti-thymocyte globulinBiological: peripheral blood lymphocyte therapyDrug: fludarabine phosphateDrug: methylprednisoloneDrug: thiotepaProcedure: allogeneic hematopoietic stem cell transplantationProcedure: in vitro-treated peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00376480
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00357396
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentDrug: Leucovorin CalciumDrug: ThiotepaDrug: MethotrexateDrug: Vincristine Sulfate
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 91
- Registration Number
- NCT00336024
- Locations
- 🇺🇸
Tulane University School of Medicine, New Orleans, Louisiana, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸NYU Langone Hospital - Long Island, Mineola, New York, United States
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
- Conditions
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2015-09-25
- Target Recruit Count
- 96
- Registration Number
- NCT00317408
- Locations
- 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪Krankenhaus Muenchen Schwabing, Munich, Germany
Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 30
- Registration Number
- NCT00313521
Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 567
- Registration Number
- NCT00303810
- Locations
- 🇩🇪
University Medical Center Hamburg - Eppendorf, Hamburg, Germany
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease
- Conditions
- Interventions
- Biological: anti-thymocyte globulinBiological: therapeutic allogeneic lymphocytesDrug: fludarabine phosphateDrug: thiotepaProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: in vitro-treated peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 21
- Registration Number
- NCT00295971
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT00238433
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.